Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

NCT04885634 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Not received funding.

Conditions

Atrial Fibrillation
Overweight and Obesity

Interventions

DRUG: Semaglutide Injectable Product
DRUG: Placebo

Sponsor

Axel Brandes

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]